Companies · Biotechnology

Kips Bay Medical, Inc.

MINNEAPOLIS · Biotechnology

Diligence memoA one-page analyst read on Kips Bay Medical, Inc. — recommendation, valuation, rhythm, risks.
$9.0M
Total raised · real
4
Rounds
5.4×
Latest step-up
Top 47%
Sector rank · raised
Series A
Latest stage · inferred · Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Kips Bay Medical, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.91× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.
  • Within the normal band (91% of peer median) for its niche.
Dormant
  • Last raise 11.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Kips Bay Medical, Inc. is one of 4293 Biotechnology companies tracked from MINNEAPOLIS. By capital raised it ranks mid-pack (ahead of 54% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · Raised $5.0M (real) Modeled valuation $10M (est)$5.0M$10MSeries APre-Seed · 2009-03-17 Raised $150K (real) Modeled valuation $8.3M (est)$150K$8.3MPre-Seed2009Pre-Seed · 2011-10-24 Raised $600K (real) Modeled valuation $33M (est)$600K$33MPre-Seed2011Seed · 2015-03-24 Raised $3.3M (real) Modeled valuation $144M (est)$3.3M$144MSeed2015+$150K+$600K+$3.3MCumulative $9.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.0M
Bridge · Series A-stage$150K · 2009smaller follow-on
Bridge · Series A-stage$600K · 2011smaller follow-on
Bridge · Series A-stage$3.3M · 2015smaller follow-on

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$144.3M
Base estimate est.
$2.3M
Conservative case
$1.1B
Upside case
$16.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $10.0M · Pre-Seed · modeled $8.3M · 2009-03-17Pre-Seed · modeled $33.1M · 2011-10-24Seed · modeled $144.3M · 2015-03-242015
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
11.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
181 mo
Avg between rounds
$199K/yr
Capital velocity
56.5 yr
On record since
1970
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.3× above median
This company$9.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.6× of median
This company$3.3M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 2.2× above median
This company$144.3M
Sector median$64.2M

Raised more than 54% of sector peers (real $). Modeled value above 65% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #66 of 111.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Dnanexus, Inc. · Series A Raised $31.6M · modeled $542.3M (est)Foresight Biotherapeutics, Inc. · Series A Raised $17.0M · modeled $542.3M (est)AuraSense Therapeutics, LLC · Series A Raised $33.6M · modeled $535.0M (est)Zyomyx Inc · Series A Raised $15.2M · modeled $514.1M (est)Champions Oncology, Inc. · Series A Raised $36.8M · modeled $506.1M (est)Thrasos Innovation Inc. · Series A Raised $14.0M · modeled $506.1M (est)Merganser Biotech, Inc. · Series A Raised $21.1M · modeled $473.5M (est)Progenics Pharmaceuticals Inc · Series A Raised $12.9M · modeled $467.2M (est)GeneWeave Biosciences, Inc. · Series A Raised $36.3M · modeled $441.0M (est)Aeglea BioTherapeutics Holdings, LLC · Series A Raised $15.8M · modeled $387.1M (est)Hydra Biosciences Inc · Series A Raised $10.5M · modeled $379.9M (est)Brainstorm Cell Therapeutics Inc. · Series A Raised $12.3M · modeled $379.6M (est)Kips Bay Medical, Inc. (this company) Raised $9.0M · modeled $144.3M (est)Kips Bay Medical, Inc.
CompanyStageRaised · realValue · estvs peer med.
Dnanexus, Inc.Series A$31.6M$542.3M3.41×
Foresight Biotherapeutics, Inc.Series A$17.0M$542.3M3.41×
AuraSense Therapeutics, LLCSeries A$33.6M$535.0M3.36×
Zyomyx IncSeries A$15.2M$514.1M3.23×
Champions Oncology, Inc.Series A$36.8M$506.1M3.18×
Thrasos Innovation Inc.Series A$14.0M$506.1M3.18×
Merganser Biotech, Inc.Series A$21.1M$473.5M2.98×
Progenics Pharmaceuticals IncSeries A$12.9M$467.2M2.94×
GeneWeave Biosciences, Inc.Series A$36.3M$441.0M2.77×
Aeglea BioTherapeutics Holdings, LLCSeries A$15.8M$387.1M2.43×
Hydra Biosciences IncSeries A$10.5M$379.9M2.39×
Brainstorm Cell Therapeutics Inc.Series A$12.3M$379.6M2.39×
Kips Bay Medical, Inc. this companySeries A$9.0M$144.3M0.91×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$150K2009-03-17$833K$8.3M90%
Pre-Seed$600K2011-10-24$3.3M$33.1M90%
Seed$3.3M2015-03-24$16.3M$144.3M90%
Series A$5.0M$22.7M$10.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$150K2009-03-17
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$600K2011-10-24
    • Raised again after 31 mo — slower than the ~14 mo sector norm.
    • Round 4.0× larger than the prior — scaling up.
  3. Seed$3.3M2015-03-24
    • Raised again after 41 mo — slower than the ~14 mo sector norm.
    • Round 5.4× larger than the prior — scaling up.
Intelligence
2030 ~Q2
Modeled next raise · ~181mo cadence
$9.8M
Modeled next size est.range $6.3M$15.6M
5.4×
Last step-up
$199K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Manny Villafana1 other2009-03
Scott Kellen1 other2011-10
Arch C. Smith2011-10
Michael E. Reinhardt2011-10
Michael Winegar2009-03
Randall K. LaBounty2011-10
Robert E. Munzenrider2011-10
Robert J. Sheehy2011-10
Registry & provenance

Kips Bay Medical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1460198
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Medical 21, Inc.BiotechnologySeries A$16.7M$102.9Mnetwork1 shared operator · same sector · same stage
DxNA LLCBiotechnologySeries A$9.0M$166.5Msame sector · same stage
Mitogenetics, LLCBiotechnologySeries A$9.2M$110.2Msame sector · same stage
Ls Biopath, Inc.BiotechnologySeries A$8.7M$156.9Msame sector · same stage
MatriSys Bioscience, Inc.BiotechnologySeries A$8.4M$113.7Msame sector · same stage
Viral Logic Systems Technology CorpBiotechnologySeries A$8.4M$121.9Msame sector · same stage
Qurgen Inc.BiotechnologySeries A$9.7M$162.7Msame sector · same stage
Cytocom Inc.BiotechnologySeries A$8.3M$167.5Msame sector · same stage
Frequently asked
How much funding has Kips Bay Medical, Inc. raised?
Kips Bay Medical, Inc. has raised approximately $9.0M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Kips Bay Medical, Inc.'s estimated valuation?
Provath's modeled valuation for Kips Bay Medical, Inc. is approximately $144.3M (modeled range $2.3M–$1.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Kips Bay Medical, Inc. at?
Kips Bay Medical, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Mar 24.
What does Kips Bay Medical, Inc. do and where is it based?
Kips Bay Medical, Inc. operates in the Biotechnology sector, based in MINNEAPOLIS.
Explore related

See where Kips Bay Medical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Kips Bay Medical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.